Over the past two decades, the promise of accelerated drug development and personalized medicine have brought heighten attention to the field of biomarker. But do you really know what biomarker are, how they are developed, and how they are used?
Here, I'll share over 15 years of experience in the fields of biomarker development and translational research to try to answer some of these questions.

Pages

Biography

Thierry Sornasse, Ph.D. is currently an independent biomarker and translational medicine consultant at Integrated Biomarker Strategy. Until January 2011, Dr. Sornasse held the position of director Biomarker Integration at Elan Pharmaceuticals, Inc. In this role, he coordinated the global biomarker strategy across Research and Development, in support of Multiple Sclerosis, Alzheimer’s, and Parkinson’s disease programs. Prior to this position, Dr. Sornasse led the In vivo Pharmacology, Neuroinflammation group at Elan, focusing on the evaluation and development of new therapeutic approaches in Multiple Sclerosis.

From 2005 to 2008, Dr. Sornasse served as director of Nonclinical Sciences at Genitope Corporation where he directed the nonclinical development of novel immunotherapy approaches for the treatment of lymphoma.

From 2003 to 2005, Dr. Sornasse held the position of Senior Scientist in the Translational Medicine group at Protein Design Labs, Inc. In this role, he investigated the mechanism of action of novel antibody therapeutics for the treatment of inflammatory diseases, focusing on the identification of new pharmacodynamic biomarkers applicable to the clinic.

From 1997 to 2002, Dr. Sornasse held multiple positions of increasing responsibilities at Incyte Genomics, focusing on the identification of novel RNA-based biomarkers of diseases and pathological processes.

Dr. Sornasse was a post-doctoral fellow at the DNAX Research Institute from 1994 to 1997. He obtained his doctorate in Immunology and his Bachelor in Cellular & Molecular Biology from the Université Libre de Bruxelles, Belgium.